Bioaffinity Technologies Inc (BIAF)

May 28, 2025, 9:00 AM EDT - 8 days ago

bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics

May 20, 2025, 9:00 AM EDT - 16 days ago

bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer

May 15, 2025, 8:30 AM EDT - 21 days ago

bioAffinity Technologies Reports First Quarter 2025 Results

May 8, 2025, 9:00 AM EDT - 4 weeks ago

Independent White Paper Highlights Real-World Impact of bioAffinity Technologies' CyPath® Lung in Diagnosing Early-Stage Lung Cancer

May 7, 2025, 1:15 PM EDT - 4 weeks ago

WallachBeth Capital Announces Closing of bioAffinity Technologies $3.25m Offering

May 7, 2025, 1:00 PM EDT - 4 weeks ago

bioAffinity Technologies Announces Closing of $3.25 Million Offering

May 6, 2025, 10:30 AM EDT - 4 weeks ago

WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.25m Offering

May 6, 2025, 9:25 AM EDT - 4 weeks ago

bioAffinity Technologies Announces Pricing of $3.25 Million Offering

Apr 17, 2025, 9:15 AM EDT - 7 weeks ago

bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost

Mar 31, 2025, 9:28 AM EDT - 2 months ago

bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024

Mar 26, 2025, 9:00 AM EDT - 2 months ago

Case Study: bioAffinity Technologies' CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer

Mar 19, 2025, 9:00 AM EDT - 2 months ago

Case Study: bioAffinity Technologies' Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence

Mar 13, 2025, 9:00 AM EDT - 3 months ago

Physicians' Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer

Mar 6, 2025, 8:00 AM EST - 3 months ago

bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth

Feb 26, 2025, 12:10 PM EST - 3 months ago

WallachBeth Capital Announces Closing of bioAffinity Technologies Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

Feb 26, 2025, 11:30 AM EST - 3 months ago

bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

Feb 25, 2025, 11:05 AM EST - 3 months ago

WallachBeth Capital Announces bioAffinity Technologies Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

Feb 25, 2025, 9:58 AM EST - 3 months ago

bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

Jan 22, 2025, 8:00 AM EST - 4 months ago

bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic

Jan 13, 2025, 8:00 AM EST - 5 months ago

bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath® Lung

Jan 10, 2025, 9:00 AM EST - 5 months ago

Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ENLV

Dec 17, 2024, 8:00 AM EST - 6 months ago

Join bioAffinity Technologies' Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19

Dec 12, 2024, 8:00 AM EST - 6 months ago

bioAffinity Technologies Set for Continued Expansion in 2025

Nov 14, 2024, 8:00 AM EST - 7 months ago

bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024

Nov 4, 2024, 8:00 AM EST - 7 months ago

bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development

Oct 30, 2024, 8:00 AM EDT - 7 months ago

bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung

Oct 21, 2024, 11:39 AM EDT - 8 months ago

WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement

Oct 21, 2024, 10:45 AM EDT - 8 months ago

bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement

Oct 18, 2024, 2:57 PM EDT - 8 months ago

WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement

Oct 18, 2024, 12:45 PM EDT - 8 months ago

bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement

Oct 16, 2024, 8:00 AM EDT - 8 months ago

bioAffinity's CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines

Oct 10, 2024, 8:00 AM EDT - 8 months ago

bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer

Oct 9, 2024, 8:00 AM EDT - 8 months ago

bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test

Sep 18, 2024, 8:00 AM EDT - 9 months ago

Peer-Reviewed Study: bioAffinity Technologies' CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis

Aug 23, 2024, 5:15 PM EDT - 10 months ago

bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO

Aug 14, 2024, 9:25 AM EDT - 10 months ago

bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath® Lung Sales

Aug 5, 2024, 2:00 PM EDT - 10 months ago

WallachBeth Capital Announces Closing of bioAffinity Technologies Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million

Aug 5, 2024, 1:17 PM EDT - 10 months ago

bioAffinity Technologies Announces Closing of Registered Direct Offering, Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million

Aug 2, 2024, 10:00 AM EDT - 10 months ago

WallachBeth Capital Announces bioAffinity Technologies Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million

Aug 2, 2024, 9:25 AM EDT - 10 months ago

bioAffinity Technologies Announces Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million

Jul 12, 2024, 9:35 AM EDT - 11 months ago

Biotricity and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Jul 9, 2024, 8:00 AM EDT - 11 months ago

bioAffinity Technologies Reports 217% Sales Growth in Second Quarter 2024 for CyPath® Lung

Jul 5, 2024, 9:00 AM EDT - 11 months ago

BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

BIVI

Jun 12, 2024, 8:00 AM EDT - 1 year ago

bioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath® Lung Tests

May 15, 2024, 9:15 AM EDT - 1 year ago

bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes

May 2, 2024, 8:00 AM EDT - 1 year ago

bioAffinity Technologies News Update

Apr 24, 2024, 8:00 AM EDT - 1 year ago

bioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of Growth

Apr 9, 2024, 8:00 AM EDT - 1 year ago

bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening

Apr 1, 2024, 9:49 AM EDT - 1 year ago

bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 8, 2024, 1:15 PM EST - 1 year ago

Wallachbeth Capital Announces Closing of bioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement